Nebius Group N.V. (NBIS)
NASDAQ: NBIS · Real-Time Price · USD
55.09
-0.08 (-0.15%)
At close: Aug 6, 2025, 4:00 PM
55.80
+0.71 (1.29%)
After-hours: Aug 6, 2025, 7:59 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $65, which forecasts a 17.99% increase in the stock price over the next year. The lowest target is $47 and the highest is $80.
Price Target: $65.00 (+17.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| DA Davidson | DA Davidson | Strong Buy Maintains $55 → $65 | Strong Buy | Maintains | $55 → $65 | +17.99% | Aug 5, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $68 | Strong Buy | Initiates | $68 | +23.43% | Jul 14, 2025 |
| DA Davidson | DA Davidson | Strong Buy Maintains $50 → $55 | Strong Buy | Maintains | $50 → $55 | -0.16% | Jun 16, 2025 |
| BWS Financial | BWS Financial | Strong Buy Maintains $60 → $80 | Strong Buy | Maintains | $60 → $80 | +45.22% | Jun 10, 2025 |
| Northland Capital Markets | Northland Capital Markets | Buy Maintains $34 → $47 | Buy | Maintains | $34 → $47 | -14.69% | May 21, 2025 |
Financial Forecast
Revenue This Year
595.08M
from 117.50M
Increased by 406.45%
Revenue Next Year
1.44B
from 595.08M
Increased by 141.48%
EPS This Year
-105.76
from -2.28
EPS Next Year
-10.47
from -105.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 663.9M | 1.6B | 2.9B |
| Avg | 595.1M | 1.4B | 2.8B |
| Low | 513.0M | 1.2B | 2.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 465.0% | 171.7% | 104.0% |
| Avg | 406.5% | 141.5% | 98.1% |
| Low | 336.6% | 94.9% | 90.4% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -101.58 | 16.59 |
| Avg | -105.76 | -10.47 |
| Low | -108.41 | -35.61 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.